journal
MENU ▼
Read by QxMD icon Read
search

Journal of Child and Adolescent Psychopharmacology

journal
https://www.readbyqxmd.com/read/28618239/extent-and-risks-of-antipsychotic-off-label-use-in-children-and-adolescents-in-germany-between-2004-and-2011
#1
Carsten Schröder, Michael Dörks, Bianca Kollhorst, Tilo Blenk, Ralf W Dittmann, Edeltraut Garbe, Oliver Riedel
OBJECTIVE: Only little is known about antipsychotic (AP) off-label use (OLU) in pediatric populations. It was the aim of this study to examine the frequency as well as the risks of off-label AP use in underaged patients. METHODS: To calculate the frequency of off-label AP prescriptions for the years 2004-2011, we used claims data of more than two million minors aged 0-17 years. Off-label prescriptions were analyzed with regard to type of OLU, physician specialty, and underlying diagnoses...
June 15, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28581341/improving-cardiometabolic-monitoring-of-children-on-antipsychotics
#2
Robert O Cotes, Nisha K Fernandes, Jennifer L McLaren, Gregory J McHugo, Stephen J Bartels, Mary F Brunette
OBJECTIVES: This study evaluated changes in cardiometabolic monitoring for children and adolescents who were prescribed an antipsychotic medication in a state mental health system before and after a quality improvement intervention. METHODS: The intervention included education for prescribers, auditing on metabolic monitoring, and feedback to mental health center leaders regarding their monitoring. Research staff extracted yearly data on cardiometabolic monitoring from randomly selected community mental health center records before and after the intervention...
June 5, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28581338/psychiatric-disorders-and-quality-of-life-in-the-offspring-of-parents-with-bipolar-disorder
#3
Michal Goetz, Antonin Sebela, Marketa Mohaplova, Silvie Ceresnakova, Radek Ptacek, Tomas Novak
OBJECTIVE: To determine current and lifetime psychopathology and assess quality of life (QoL) in offspring of a parent with bipolar disorder (BD). METHODS: We investigated 43 offspring of bipolar parents (high-risk offspring [HRO]) (mean age 12.5 ± 3.1; range 6.7-17.9 years) and 43 comparison offspring matched for sex, age, and IQ of healthy parents. Lifetime and current presence of Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (DSM-5) diagnoses were assessed using Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version (K-SADS-PL)...
June 5, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28557548/efficacy-and-safety-of-a-chewable-methylphenidate-extended-release-tablet-in-children-with-attention-deficit-hyperactivity-disorder
#4
Sharon B Wigal, Ann Childress, Sally A Berry, Heidi Belden, Faith Walters, Phillip Chappell, Nancy Sherman, John Orazem, Donna Palumbo
OBJECTIVE: This phase 3, laboratory classroom study assessed the efficacy and safety of methylphenidate hydrochloride extended-release chewable tablets (MPH ERCT) compared with placebo in children with attention-deficit/hyperactivity disorder (ADHD). METHODS: Following a 6-week, open-label, dose-optimization period, children 6-12 years of age (n = 90) with ADHD were randomly assigned to double-blind MPH ERCT at the final optimized dose (20-60 mg/day) or placebo...
May 30, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28520464/suvorexant-for-the-treatment-of-insomnia-in-adolescents
#5
Kentaro Kawabe, Fumie Horiuchi, Marina Ochi, Kayoko Nishimoto, Shu-Ichi Ueno, Yasunori Oka
OBJECTIVES: Suvorexant is the first dual orexin receptor antagonist for treating insomnia. This study aimed to evaluate the tolerability, efficacy, and safety of suvorexant on insomnia in adolescents. METHODS: Thirty patients (8 male and 22 female; mean standard deviation age: 15.7 ± 2.4 years; range: 10-20) with insomnia were administered suvorexant. Clinical background, persistence rate, the Clinical Global Impression (CGI), and the Athens Insomnia Scale (AIS) were compared between patients who continued and discontinued suvorexant treatment...
May 18, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28509573/adverse-events-of-atomoxetine-in-a-double-blind-placebo-controlled-study-in-children-with-autism
#6
Rameshwari V Tumuluru, Patricia Corbett-Dick, Michael G Aman, Tristram Smith, L Eugene Arnold, Xueliang Pan, Kristin A Buchan-Page, Nicole V Brown, Melissa M Ryan, Susan L Hyman, Jessica Hellings, Craig Williams, Jill A Hollway, Luc Lecavalier, Robert R Rice, Sarah McAuliffe-Bellin, Benjamin L Handen
OBJECTIVE: Attention-deficit/hyperactivity disorder (ADHD) symptoms, including inattention and over activity, occur in approximately one-third of children with autism spectrum disorder (ASD). We describe the rate and duration of adverse events in a randomized controlled trial of atomoxetine (ATX) and parent training (PT) for ADHD symptoms and noncompliance in children with ASD. METHODS: We conducted a 10-week, double-blind, 2 × 2 trial of ATX and PT with 128 children (ages 5-14) randomized to ATX alone, ATX+PT, placebo+PT, or placebo alone...
May 16, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28498053/autism-behavior-inventory-a-novel-tool-for-assessing-core-and-associated-symptoms-of-autism-spectrum-disorder
#7
Abi Bangerter, Seth Ness, Michael G Aman, Anna J Esbensen, Matthew S Goodwin, Geraldine Dawson, Robert Hendren, Bennett Leventhal, Anzalee Khan, Mark Opler, Adrianne Harris, Gahan Pandina
OBJECTIVE: Autism Behavior Inventory (ABI) is a new measure for assessing changes in core and associated symptoms of autism spectrum disorder (ASD) in participants (ages: 3 years-adulthood) diagnosed with ASD. It is a web-based tool with five domains (two ASD core domains: social communication, restrictive and repetitive behaviors; three associated domains: mental health, self-regulation, and challenging behavior). This study describes design, development, and initial psychometric properties of the ABI...
May 12, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28481642/micronutrient-therapy-for-violent-and-aggressive-male-youth-an-open-label-trial
#8
Jessica L Hambly, Kelly Francis, Sohil Khan, Kristen S Gibbons, William J Walsh, Brett Lambert, Chris Testa, Alison Haywood
OBJECTIVES: Pharmacotherapy for problematic aggressive and violent behavior disorders in male children and adolescents is associated with significant adverse events. Treatments with more acceptable risk-benefit ratios are critically needed. Micronutrient intervention will be investigated as an alternative to bridge the therapeutic gap in the management of these behaviors. METHODS: Males aged 4-14 who displayed ongoing violent and aggressive behaviors received micronutrient intervention containing alpha-tocopherol (vitamin E), ascorbic acid (vitamin C), biotin, chromium, pyridoxal-5-phosphate (P5P), pyridoxine (vitamins B6), selenium, and zinc, in a 16-week open-label trial...
May 8, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28475373/efficacy-and-safety-of-lurasidone-in-adolescents-with-schizophrenia-a-6-week-randomized-placebo-controlled-study
#9
Robert Goldman, Antony Loebel, Josephine Cucchiaro, Ling Deng, Robert L Findling
OBJECTIVE: To evaluate the efficacy and safety of lurasidone in acutely symptomatic adolescent patients with schizophrenia. METHODS: Patients aged 13-17 years were randomly assigned to 6 weeks of double-blind, fixed-dose lurasidone (40 or 80 mg/day) or placebo. Primary and key secondary efficacy measures were change from baseline to week 6 in the Positive and Negative Symptom Scale (PANSS) total score and Clinical Global Impressions-Severity (CGI-S) score, respectively, using mixed model for repeated measurement (MMRM) analysis...
May 5, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28475372/outcomes-in-child-psychiatry
#10
Jon M McClellan, John Scott Werry
No abstract text is available yet for this article.
May 5, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28475355/review-of-salient-investigational-drugs-for-the-treatment-of-fragile-x-syndrome
#11
Kaizad Munshi, Katherine Pawlowski, Joseph Gonzalez-Heydrich, Jonathan D Picker
OBJECTIVES: Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability, in addition to being the commonest diagnosable cause of autism. The identification of the biochemical mechanism underlying this disorder has provided amenable targets for therapy. This review aims to provide an overview of investigational drug therapies for FXS. METHODS: The authors carried out a search of clinical and preclinical trials for FXS in PubMed and on the U...
May 5, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28453334/different-immune-signature-in-youths-experiencing-antipsychotic-induced-weight-gain-compared-to-untreated-obese-patients
#12
Simone Pisano, Gennaro Catone, Giangennaro Coppola, Marco Carotenuto, Raffaella Iuliano, Claudia Tiano, Anna Rita Montesanto, Vittoria D'Esposito, Emanuele Del Giudice Miraglia, Pietro Formisano, Carmela Bravaccio
OBJECTIVES: To assess cytokine and chemokine levels in youth experiencing antipsychotic-induced weight gain (AIWG) compared to obese patients, hypothesizing a different "immune signature" between the two kinds of obesity. METHODS: We compared a group of youth experiencing AIWG (N 19, mean age 159 months, mean body mass index [BMI] z-score 1.81) and an age-, gender-, and BMI-matched group of untreated obese patients (N 19, mean age 147 months, mean BMI z-score 2) for a wide range of cytokines and chemokines by using a multiplex ELISA test...
April 28, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28441041/the-child-network-for-parents-to-track-their-child-s-mood-and-behavior
#13
Robert M Post, Michael Rowe, Dana Kaplan, Robert Findling
INTRODUCTION: A wide range of psychiatric disorders are common in young children, especially in those at high risk because of a parent with a unipolar or bipolar mood disorder in the United States. Yet in part because most children are seen in primary care, these illnesses are often not recognized or treated in a timely fashion. To begin to address this problem, we started the Child Network. METHODS: The Child Network is for parents of children age 2-12 with mood or behavioral symptoms or at high risk for them...
April 25, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28409660/a-randomized-double-blind-placebo-controlled-trial-on-effectiveness-and-safety-of-celecoxib-adjunctive-therapy-in-adolescents-with-acute-bipolar-mania
#14
Seyed Yaser Mousavi, Rasoul Khezri, Mohammad-Ali Karkhaneh-Yousefi, Payam Mohammadinejad, Faezeh Gholamian, Mohammad Reza Mohammadi, Atefeh Zeinoddini, Shahin Akhondzadeh
OBJECTIVE: Recent studies have focused on the role of inflammatory cascades as one of the possible etiologic factors of bipolar disorder. We hypothesize that celecoxib, through its anti-inflammatory properties, may have a therapeutic role in acute bipolar mania. PATIENTS AND METHODS: Forty-two adolescent inpatients with the diagnosis of acute bipolar mania participated in a parallel, randomized, double-blind controlled trial, and 40 patients underwent an 8-week treatment with either celecoxib (100 mg twice daily) or placebo as an adjunctive treatment to lithium and risperidone...
April 14, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28402139/long-term-open-label-safety-study-of-edivoxetine-monotherapy-in-children-and-adolescents-with-attention-deficit-hyperactivity-disorder
#15
Emel Serap Monkul Nery, Mark Bangs, Peng Liu, Jonna Ahl, David Perahia
OBJECTIVE: The purpose of this study was to assess the long-term safety and tolerability of edivoxetine, a selective norepinephrine reuptake inhibitor, which was being developed as monotherapy in pediatric attention-deficit/hyperactivity disorder (ADHD). METHODS: This was an open-label study of edivoxetine once daily dosing (0.1-0.3 mg/kg) as treatment for ADHD in children (6-11 years) and adolescents (12-17 years) to assess safety for up to 5 years. The safety assessments included the incidence of adverse events, vital signs, electrocardiograms, laboratory tests, percentile changes in weight, height, and body mass index, and Tanner staging...
April 12, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28394175/early-morning-functional-impairments-in-stimulant-treated-children-with-attention-deficit-hyperactivity-disorder-versus-controls-impact-on-the-family
#16
Stephen V Faraone, Russell J Schachar, Russell A Barkley, Rick Nullmeier, F Randy Sallee
OBJECTIVE: Children with attention-deficit/hyperactivity disorder (ADHD) frequently manifest early morning functional (EMF) impairments before school. We conducted a quantitative research survey to assess the impact of these EMF impairments on the family unit (caregiver, spouse/partner, and siblings). STUDY DESIGN: We developed an online survey questionnaire to collect data from 300 primary caregivers of children with ADHD and 50 primary caregivers of children who did not have ADHD...
April 10, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28394174/modified-release-methylphenidate-related-trichotillomania-in-a-boy-with-autism-spectrum-disorder
#17
Serkan Gunes
No abstract text is available yet for this article.
April 10, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28387528/palatal-petechiae-in-the-absence-of-group-a-streptococcus-in-pediatric-patients-with-acute-onset-neuropsychiatric-deterioration-a-cohort-study
#18
Talia Mahony, Douglas Sidell, Hayley Gans, Michael Cooperstock, Kayla Brown, Joanne M Cheung, Bahare Farhadian, Melissa Gustafson, Margo Thienemann, Jennifer Frankovich
BACKGROUND: Palatal petechiae are 95% specific for streptococcal pharyngitis. Despite this, and despite prior research demonstrating that Group A Streptococcus (GAS) is a common antecedent to pediatric acute-onset neuropsychiatric syndrome (PANS) episodes, we anecdotally observed a low rate of documented GAS in patients with PANS and palatal petechiae. This retrospective chart review was conducted to formally report the rate of palatal petechiae and concurrent GAS in a cohort of patients with PANS and investigate other etiologic factors...
April 7, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28384010/placebo-response-in-pediatric-anxiety-disorders-results-from-the-child-adolescent-anxiety-multimodal-study
#19
Jeffrey R Strawn, Eric T Dobson, Jeffrey A Mills, Gary J Cornwall, Dara Sakolsky, Boris Birmaher, Scott N Compton, John Piacentini, James T McCracken, Golda S Ginsburg, Phillip C Kendall, John T Walkup, Anne Marie Albano, Moira A Rynn
OBJECTIVES: The aim of this study is to identify predictors of pill placebo response and to characterize the temporal course of pill placebo response in anxious youth. METHODS: Data from placebo-treated patients (N = 76) in the Child/Adolescent Anxiety Multimodal Study (CAMS), a multisite, randomized controlled trial that examined the efficacy of cognitive-behavioral therapy, sertraline, their combination, and placebo for the treatment of separation, generalized, and social anxiety disorders, were evaluated...
April 6, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28383998/effectiveness-and-side-effect-profile-of-stimulant-medication-for-the-treatment-of-attention-deficit-hyperactivity-disorder-in-youth-with-epilepsy
#20
Mary C Kral, Michelle D Lally, Andrea D Boan
OBJECTIVES: This clinical case series examined the effectiveness and potential side effects associated with stimulant medication for the treatment of attention-deficit/hyperactivity disorder (ADHD) in 20 youth with epilepsy. METHODS: Response to stimulant medication was examined through symptom reduction on the Conners-Third Edition: Parent Rating Scale, Short Form [Conner 3-P(S)], which was administered to caregivers before initiation of treatment and following dosage titration to achieve therapeutic efficacy...
April 6, 2017: Journal of Child and Adolescent Psychopharmacology
journal
journal
20144
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"